12:00 AM
Sep 07, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Catena idebenone regulatory update

Santhera initiated a European named-patient program to provide access to Catena idebenone for patients with Friedreich's Ataxia (FRDA). The program will be managed by IDIS World Medicines Ltd. (Weybridge, U.K.). The company markets Catena for FRDA in Canada. Santhera received a negative opinion from EMEA's...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >